长春瑞宾联合不同铂类治疗晚期非小细胞肺癌的比较

Vinorelbine plus different platinum drugs for advanced non-small cell lung cancer

目的观察长春瑞宾分别联合顺铂、奈达铂、奥沙利铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效及毒副反应。方法可评价疗效的NSCLC患者均为初治患者,其中长春瑞滨联合顺铂治疗(NP组)30例,长春瑞宾联合奈达铂治疗(NN组)30例,长春瑞滨联合奥沙利铂治疗(NL组)35例。结果 NP组总有效率为46.67%,NN组总有效率为40.00%,NL组总有效率为37.14%。各组近期疗效比较差异无统计学意义(P>0.05);主要毒副反应为骨髓抑制、胃肠道反应及神经毒性。结论 长春瑞宾分别联合顺铂、奈达铂、奥沙利铂治疗晚期NSCLC的近期疗效无明显差异,联合奥沙利铂或奈达铂治疗晚期NSCLC疗效确切,患者耐受性良好,为晚期NSCLC的治疗提供了新的选择。

Objective To evaluate the efficacy and side effect of Vinorelbine plus Cisplatin or Nedaplatin or Oxaliplatin in patients with advanced non-small-cell lung cancer（NSCLC）.Methods The 30 evaluable cases in NP group were treated with Vinorelbine plus Cisplatin,the 30 evaluable cases in NN group were treated with Vinorelbine plus Nedaplatin,and the 35 evaluable cases in NL group were treated with Vinorelbine plus Oxaliplatin.Results The response rate was 46.67% in NP group,40.00% in NN group and 37.14% in NL groups respectively.The main toxicity includes myelosuppression,gastrointestinal disorders and neurotoxicity.Conclusions There is no statistical difference among the three therapies.Due to good efficacy and tolerability,Vinorelbine plus Oxaliplatin or Nedaplatin offer new choices for treating advanced NSCLC.